Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
18 Junho 2024 - 5:01PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, announced today that Chris Hall, CEO and President,
will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx
Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m.
Eastern Time.
About Personalis, Inc.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest timepoints, enable the selection of
targeted therapies based on ultra-comprehensive genomic profiling,
and enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and X
(Twitter).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618438450/en/
Investors: Caroline Corner investors@personalis.com
415-202-5678
Media Contact: pr@personalis.com
Personalis (NASDAQ:PSNL)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Personalis (NASDAQ:PSNL)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
